Syngene International

Syngene reported Q4 FY26 revenue of ₹1,037 croreCurrent reported value: ₹1,037 crore. No comparable prior figure is available in the source record. (+2Current reported value: 2. No comparable prior figure is available in the source record.% YoY, +13%Current 13%. Reported change: +13% QoQ. QoQ) and EBITDA margin of 29%Current reported value: 29%. No comparable prior figure is available in the source record., beating revised guidance. Full-year revenue grew 3%Current reported value: 3%. No comparable prior figure is available in the source record. to ~₹4,190 crore, impacted by the Librella destocking headwind. PAT before exceptional items was ₹153 croreCurrent reported value: ₹153 crore. No comparable prior figure is available in the source record. (-16Current reported value: -16. No comparable prior figure is available in the source record.% YoY). Management guided for a broadly flat FY27 with EBITDA margins in the mid-20s, as Librella revenue largely disappears in H1. The Bristol-Myers Squibb partnership extension to 2035 and investments in ADC, peptides, and biologics position the company for growth from FY28. Key risk: Librella revenue declines faster than new contracts ramp up, pressuring near-term revenue.